Ansbert Gadicke is on the Board of Directors at Cullinan and a co-founder and Managing Director of MPM Capital and its venture capital activities as well as an investment committee member of its oncology-only crossover investment strategy (both public and private equities).
Ansbert co-founded MPM in 1997 with his partner Luke Evnin and was the lead investor and has served on the boards of several of MPM’s most successful investments including BioMarin, Idenix, Mitobridge, Pharmasset, and Radius. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and previously, he was at The Boston Consulting Group.
Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. He is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.
Ansbert received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at MIT and the Biochemistry Department at Harvard University. While at the German Cancer Research Center he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.
Ansbert currently serves as Chairman of the Board at TCR2 Therapeutics and as a Board Director at ElevateBio and iTeos Therapeutics.
What is Ansbert Gadicke's net worth?
The estimated net worth of Ansbert Gadicke is at least $4.78 million as of September 13th, 2021. Dr. Gadicke owns 248,170 shares of Cullinan Oncology stock worth more than $4,777,273 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Gadicke may own. Learn More about Ansbert Gadicke's net worth.
How do I contact Ansbert Gadicke?
Has Ansbert Gadicke been buying or selling shares of Cullinan Oncology?
Ansbert Gadicke has not been actively trading shares of Cullinan Oncology during the last quarter. Most recently, Ansbert Gadicke sold 888 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $29.16, for a transaction totalling $25,894.08. Learn More on Ansbert Gadicke's trading history.
Who are Cullinan Oncology's active insiders?
Are insiders buying or selling shares of Cullinan Oncology?
During the last twelve months, insiders at the sold shares 21 times. They sold a total of 126,339 shares worth more than $1,727,655.68. The most recent insider tranaction occured on February, 1st when insider Corrine Savill sold 40,000 shares worth more than $647,200.00. Insiders at Cullinan Oncology own 8.8% of the company.
Learn More about insider trades at Cullinan Oncology. Information on this page was last updated on 2/1/2024.
